Somerset, Wis.-based medical supplier SMC Ltd. has acquired a new facility in Charlotte, N.C., to expand its portfolio of services for its pharmaceutical clients.
The plant will include lab-to-market development, analytical services, device manufacture, sterile fill and finish, final assembly and secondary packaging.
"There are notable developments in the injectables market — the growth of more complex biologics and the increased interest in delivering large volumes of API," Uri Baruch, vice president and general manager of SMC, said in a news release.
"We believe our ability to deliver, at speed, fill volumes from 1 milliliter to 50ml is an unmet need and is already attracting significant attention from our clients and partners.
"This acquisition not only adds to this capability, it reaffirms our commitment to the pharma market and completes another phase of our growth agenda," Baruch added.
"We are still in the early stage of the build out of our North Carolina facility," Christie Wanderer, director of brand and marketing communications, told PN in an email. Wanderer declined to comment further on the expansion.
In 2021, the contract manufacturer expanded its manufacturing facility in Costa Rica by about 60,000 square feet, doubling its size.
"At SMC, we have a proud 36-year history of innovating for contract manufacturing and pharma services customers," said Chetan Patel, SMC Ltd.'s CEO. "This new North Carolina facility is another example of SMC adding the expertise, capabilities, and capacity our customers need to be successful. We know North Carolina's fill finish capabilities will allow SMC and our pharmaceutical customers to form deeper partnerships well into the future."
With other locations in California, Wisconsin, Massachusetts, Ohio, the United Kingdom and India, SMC also offers design, finished device thermoplastic molding, liquid injection molding, micro molding, and kitting and packaging of finished devices with ISO 13485 systems, white room, class 7 and 8 clean rooms.